Oropharyngeal squamous cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:14:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Oropharyngeal squamous cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Reducing Treatment Intensity for Patients with HPV-Positive Oropharyngeal Cancer Using Cisplatin and Carboplatin https://clinicaltrials.eu/trial/study-on-reducing-treatment-intensity-for-patients-with-hpv-positive-oropharyngeal-cancer-using-cisplatin-and-carboplatin/ Wed, 29 Apr 2026 15:02:42 +0000 https://clinicaltrials.eu/trial/study-on-reducing-treatment-intensity-for-patients-with-hpv-positive-oropharyngeal-cancer-using-cisplatin-and-carboplatin/ This clinical trial is focused on studying Human papillomavirus (HPV)-positive oropharyngeal cancer, a type of throat cancer linked to the HPV virus. The study aims to explore the effects of reducing the intensity of additional treatments after surgery, specifically looking at how this might improve swallowing function and reduce side effects. The treatments being studied include two chemotherapy drugs, Cisplatin and Carboplatin, which are given through an intravenous infusion, meaning they are administered directly into the bloodstream through a vein.

The purpose of the study is to determine if a less intense treatment approach can maintain the same level of effectiveness in terms of overall survival while improving the quality of life for patients. Participants in the study will undergo surgery to remove the cancer, followed by a reduced intensity of additional treatments. The study will monitor the participants’ swallowing abilities and overall health over time to assess the impact of the treatment changes.

Throughout the study, researchers will collect information on the participants’ survival rates and any side effects experienced. The goal is to find a balance between effective cancer treatment and minimizing the negative impact on patients’ daily lives, particularly focusing on their ability to swallow and overall well-being. This research could lead to improved treatment protocols for individuals with HPV-positive oropharyngeal cancer in the future.

]]> Study on the Safety and Effectiveness of Afatinib for Fanconi Anemia Patients with Advanced Squamous Cell Carcinoma in the Oral Cavity, Oropharynx, Hypopharynx, or Larynx https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-afatinib-for-fanconi-anemia-patients-with-advanced-squamous-cell-carcinoma-in-the-oral-cavity-oropharynx-hypopharynx-or-larynx/ Wed, 29 Apr 2026 15:01:07 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-afatinib-for-fanconi-anemia-patients-with-advanced-squamous-cell-carcinoma-in-the-oral-cavity-oropharynx-hypopharynx-or-larynx/ This clinical trial is focused on studying the effects of a medication called Afatinib in patients with a rare genetic disorder known as Fanconi anemia. This disorder can lead to a type of cancer called squamous cell carcinoma, which affects areas such as the mouth, throat, and voice box. The study aims to understand how safe and effective Afatinib is when used to treat these cancers, especially when they cannot be surgically removed or have spread to other parts of the body.

The treatment involves taking Afatinib in the form of film-coated tablets, which are taken orally. The study will compare the effects of different doses of Afatinib to see how well it works in controlling the cancer and improving the quality of life for patients. Participants will be monitored for any side effects and how their cancer responds to the treatment over a period of time.

The purpose of this study is to gather information on the effectiveness of Afatinib in treating cancers associated with Fanconi anemia. The study will also look at how long the treatment effects last, the overall survival of patients, and any changes in their health-related quality of life. This information will help in understanding the potential benefits and risks of using Afatinib for this specific group of patients.

]]> Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-for-patients-with-advanced-head-and-neck-cancer-after-chemoradiation/ Wed, 29 Apr 2026 14:59:19 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-for-patients-with-advanced-head-and-neck-cancer-after-chemoradiation/ This study focuses on patients with locally advanced head and neck squamous cell carcinoma, a type of cancer that develops in the cells lining the mouth, throat, or surrounding areas. The research examines two medications: pembrolizumab and lenvatinib. These medications will be given to patients after they have completed their initial cancer treatment with chemotherapy and radiation therapy.

The purpose of this research is to determine if using both pembrolizumab and lenvatinib together works better than using pembrolizumab alone in preventing cancer from returning. Pembrolizumab is given through an intravenous infusion into a vein, while lenvatinib is taken as oral capsules. The treatment period may last up to 47 weeks.

The study will include patients whose cancer cells have a specific characteristic called PD-L1, which is a protein found on some cancer cells. Patients will receive regular medical check-ups throughout the study period to monitor their health and evaluate how well the treatment is working. The medications being studied are designed to help the body’s immune system fight cancer cells.

]]> Study on Reducing Chemoradiotherapy for HPV-Related Oropharyngeal Cancer Using Cisplatin for Patients with Squamous Cell Carcinoma https://clinicaltrials.eu/trial/study-on-reducing-chemoradiotherapy-for-hpv-related-oropharyngeal-cancer-using-cisplatin-for-patients-with-squamous-cell-carcinoma/ Wed, 29 Apr 2026 14:58:22 +0000 https://clinicaltrials.eu/trial/study-on-reducing-chemoradiotherapy-for-hpv-related-oropharyngeal-cancer-using-cisplatin-for-patients-with-squamous-cell-carcinoma/ This clinical trial is focused on studying a type of throat cancer called oropharyngeal squamous cell carcinoma, which is linked to the human papillomavirus (HPV). The treatment being tested in this study is called cisplatin, a medication that is given through a vein in the arm. The purpose of the study is to see if reducing the intensity of the usual treatment, which combines chemotherapy and radiation, can still effectively control the cancer over two years while minimizing side effects.

Participants in the study will receive a treatment plan that involves the use of cisplatin over a period of time. The study will monitor how well the cancer is controlled locally, meaning in the area where it started, and will also look at any side effects that occur. The study aims to find out if this adjusted treatment approach can maintain control over the cancer and improve the quality of life for patients.

Throughout the study, researchers will also gather information on overall survival rates, survival without the disease, and any spread of the cancer to other parts of the body. They will also examine the reliability of a specific biomarker called p16, which is used to help identify this type of cancer. The study will compare results between people who smoke and those who do not, to see if there are differences in how the cancer behaves. The study is expected to continue until 2029.

]]> Study on Niraparib and Dostarlimab for Patients with HPV-Negative Head and Neck Squamous Cell Carcinoma https://clinicaltrials.eu/trial/study-on-niraparib-and-dostarlimab-for-patients-with-hpv-negative-head-and-neck-squamous-cell-carcinoma/ Wed, 29 Apr 2026 14:58:03 +0000 https://clinicaltrials.eu/trial/study-on-niraparib-and-dostarlimab-for-patients-with-hpv-negative-head-and-neck-squamous-cell-carcinoma/ This clinical trial is focused on studying a type of cancer called HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC). The study will use a combination of two treatments: Niraparib, which is a medication taken as a tablet, and Dostarlimab, which is given through an infusion into a vein. Niraparib is also known by its code name MK-4827, and Dostarlimab is sometimes referred to as TSR-042.

The purpose of the study is to evaluate how effective this combination of treatments is for patients with HNSCC. Participants in the study will receive these treatments over a period of time, and their progress will be monitored. The study will include an initial phase where the safety of the treatments is assessed, followed by a longer period where the effectiveness of the treatments is evaluated. This will involve regular check-ups and possibly imaging tests like MRI to see how the cancer responds to the treatment.

Throughout the study, the safety of the treatments will be closely monitored, especially after surgery, to ensure that any side effects are managed. The study will also look at how the cancer responds to the treatments and whether there are any changes in the cancer’s genetic makeup. The goal is to understand better how these treatments can help manage HNSCC and improve outcomes for patients with this type of cancer.

]]> Study Comparing Cisplatin and Radiotherapy with Durvalumab and Radiotherapy for Patients with Intermediate Risk HPV-Positive Oropharyngeal Cancer https://clinicaltrials.eu/trial/study-comparing-cisplatin-and-radiotherapy-with-durvalumab-and-radiotherapy-for-patients-with-intermediate-risk-hpv-positive-oropharyngeal-cancer/ Wed, 29 Apr 2026 14:47:35 +0000 https://clinicaltrials.eu/trial/study-comparing-cisplatin-and-radiotherapy-with-durvalumab-and-radiotherapy-for-patients-with-intermediate-risk-hpv-positive-oropharyngeal-cancer/ This clinical trial is focused on studying a type of cancer called Oropharyngeal Squamous Cell Carcinoma, which affects the throat area. The study is specifically looking at cases that are linked to a virus known as HPV (Human Papillomavirus) and are considered to be at an intermediate risk level. The trial is comparing different treatment combinations to see which is more effective in preventing the cancer from coming back or spreading. The treatments being tested include a drug called Durvalumab, another drug called Cisplatin, and a treatment method called radiotherapy, which uses high-energy rays to target and kill cancer cells.

The purpose of the study is to evaluate how well these treatments work in terms of event-free survival, which means the length of time patients remain free from certain negative events related to their cancer. Participants in the study will receive one of the following treatment plans: radiotherapy combined with Cisplatin, radiotherapy combined with Durvalumab followed by additional Durvalumab, or radiotherapy combined with Durvalumab followed by a combination of Tremelimumab and Durvalumab. The study will monitor patients over a period to assess the effectiveness and safety of these treatments.

Throughout the study, participants will undergo regular check-ups and assessments to track their health and the progress of their treatment. The study aims to provide valuable information that could help improve treatment options for patients with this type of cancer in the future. The trial is expected to continue until 2026, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatments being tested.

]]>